Avid Bioservices Inc (CDMO)

[biopharm]

DD.. you never read the full article? : )

It clearly states in the last paragraph ( as Bavi is not being shelved! )

"Cotara and our lead oncology therapeutic candidate, bavituximab both represent significant opportunities. With key data from Phase II bavituximab clinical trials in several oncology indications set to read out in the coming months and the opportunity to advance Cotara into a pivotal trial, we have number of potentially significant value drivers on the horizon. We look forward to updating you further as we continue to make progress in our late stage clinical programs."